A population-based study on the familial aggregation of cutaneous malignant melanoma in Iceland

被引:3
作者
Eldon, Bjarki Jonsson
Thorlacius, Steinunn
Jonsson, Thorvaldur
Jonasson, Jon Gunnlaugur
Kjartansson, Jens
Bodvarsson, Sigurdur
Steingrimsson, Eirikur
Rafnar, Thorunn
机构
[1] Iceland Genom Corp, IS-105 Reykjavik, Iceland
[2] Landspitali Univ Hosp, IS-101 Reykjavik, Iceland
[3] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland
[4] Iceland Canc Registry, IS-105 Reykjavik, Iceland
关键词
malignant melanoma; familial aggregation; risk ratio; Iceland;
D O I
10.1016/j.ejca.2005.11.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to characterize the familial nature of cutaneous malignant melanoma (CMM) in Iceland. Risk ratio was used to estimate the risk among relatives of all CMM index cases diagnosed in Iceland over a 45-year period (1955-1999), using data from the National Cancer Registry and a genealogy database that covers the whole of Iceland's population. First-, second-, and third-degree relatives of CMM patients did not have an increased risk of the disease, and no added risk of other types of cancer among relatives was observed, except for thyroid cancer in first-degree male relatives. Seven individuals were diagnosed with two or more primary CMM in this period; none of these individuals had a first or second-degree relative with CMM. Altogether, 2.4% of cases were familial, as defined by commonly used criteria. In conclusion, high-penetrance susceptibility genes do not contribute much to CMM in the Icelandic population. The great majority of CMM cases in Iceland are most likely caused by the interplay between environmental causes and low-risk genes. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:922 / 926
页数:5
相关论文
共 45 条
[1]   Cancer as a complex phenotype: Pattern of cancer distribution within and beyond the nuclear family [J].
Amundadottir, LT ;
Thorvaldsson, S ;
Gudbjartsson, DF ;
Sulem, P ;
Kristjansson, K ;
Arnason, S ;
Gulcher, JR ;
Bjornsson, J ;
Kong, A ;
Thorsteinsdottir, U ;
Stefansson, K .
PLOS MEDICINE, 2004, 1 (03) :229-236
[2]   Sporadic multiple primary melanoma cases:: CDKN2A germline mutations with a founder effect [J].
Auroy, S ;
Avril, MF ;
Chompret, A ;
Pham, D ;
Goldstein, AM ;
Bianchi-Scarrá, G ;
Frebourg, T ;
Joly, P ;
Spatz, A ;
Rubino, C ;
Demenais, F ;
Bressac-de Paillerets, B .
GENES CHROMOSOMES & CANCER, 2001, 32 (03) :195-202
[3]   Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample [J].
Begg, CB ;
Orlow, I ;
Hummer, AJ ;
Armstrong, BK ;
Kricker, A ;
Marrett, LD ;
Millikan, RC ;
Gruber, SB ;
Anton-Culver, H ;
Zanetti, R ;
Gallagher, RP ;
Dwyer, T ;
Rebbeck, TR ;
Mitra, N ;
Busam, K .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (20) :1507-1515
[4]  
Bergman W, 1996, NEW ENGL J MED, V334, P471
[5]  
Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894
[6]   High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families [J].
Borg, Å ;
Sandberg, T ;
Nilsson, K ;
Johannsson, O ;
Klinker, M ;
Måsbäck, A ;
Westerdahl, J ;
Olsson, H ;
Ingvar, C .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1260-1266
[7]  
Borg A, 1996, CANCER RES, V56, P2497
[8]   MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations [J].
Box, NF ;
Duffy, DL ;
Chen, W ;
Stark, M ;
Martin, NG ;
Sturm, RA ;
Hayward, NK .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) :765-773
[9]  
Breslow NE, 1987, STAT METHODS CANC RE, VII
[10]  
Ciotti P, 1996, NEW ENGL J MED, V334, P469